米氮平与帕罗西汀治疗中国抑郁症患者疗效及安全性的Meta分析

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (2114 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To assess the efficacy and safety of mirtazapine and paroxetine on depression in Chinese patients. Methods: The randomized controlled trials (RCT) comparing the efficacy of mirtazapine and paroxetine in the treatment of depression were systematically evaluated. Evidence-based medicine research methods were applied and statistical analysis software Revman 5.2 was used. Results: Fourteen studies of RCT met inclusion criteria. The results of Meta-analysis showed that: ①After 6-weeks treatment, both the efficiency and cure rates had no significant difference between the mirtazapine and the paroxetine groups with [OR=1.15, 95% CI (0.79, 1.68), P=0.46] and [OR=1.17, 95% CI (0.86, 1.58), P=0.24]. The Hamilton Depression Scale (HAMD) scores were significantly lower in mirtazapine group than that in paroxetine group at 1 and 2 weeks after treatment, and there were no significant differences between mirtazapine group and paroxetine group at 4 and 6 weeks after treatment. ②Adverse reactions: The somnolence and weight gain rate of the mirtazapine group were higher than those of the paroxetine group with RR=2.40 and 95% CI 1.33 to 4.32, RR=10.06 and 95% CI 4.55 to 22.22. And paroxetine more easily led to dry mouth, nausea, insomnia and sexual dysfunction with RR=0.45 and 95% CI 0.31 to 0.67; RR=0.07 and 95% CI 0.03 to 0.17; RR=0.12 and 95% CI 0.04 to 0.34; RR=0.11 and 95% CI 0.04 to 0.27 than mirtazapine. The other common side reactions had no significantly different between the two groups. Conclusion: Mirtazapine has similar long term treatment effect as paroxetine, but it has a rapid-action profile. Mirtazapine can more easily induce somnolence and weight gain, and is with lower dry mouth, nausea, insomnia and sexual dysfunction rate when compared with paroxetine. And there is no significant difference between two group in other common side reactions.

Key words： mirtazapine,paroxetine,depression,RCT,Meta-analysis

Received: 27 April 2013

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Keyang
	HUANG Hanjin
	WANG Xiaotong.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2014/V44/I1/39

[1] Holden C. Mental health. Global survey examines impact of depression[J]. Science, 2000, 288(5463): 39-40.
[2] 赵宏, 徐秀杰, 王雅珍. 米氮平和帕罗西汀治疗抑郁症对照研究[J]. 临床精神医学杂志, 2004, 14(1): 35.
[3] 汤臻, 李鸣. 米氮平与帕罗西汀治疗伴有焦虑症状抑郁症的对照研究[J]. 中国心理卫生杂志, 2005, 19(9): 643-645.
[4] 吴胜, 张代江. 米氮平与帕罗西汀治疗伴躯体症状抑郁症的对照分析[J]. 第三军医大学学报, 2009, 31(22): 2290-2291.
[5] 方旭东, 林存鑫, 姚圣祥, 等. 米氮平与帕罗西汀治疗抑郁症的对照研究[J]. 中国药业杂志, 2006, 15(10): 58-59.
[6] 李艳, 王晓玉, 孙学君, 等. 米氮平与帕罗西汀治疗抑郁症的对照研究[J]. 中国医药导报, 2007, 4(18): 62.
[7] 邹晓华, 何莲英, 周云芳, 等. 米氮平与帕罗西汀治疗抑郁症的疗效比较[J]. 医药导报, 2008, 27(6): 673-674.
[8] 杭荣华, 许平, 王瑞权. 米氮平与帕罗西汀治疗抑郁症的临床研究[J]. 山东精神医学杂志, 2005, 18(4): 225-226.
[9] 邹建华, 景燕玲, 宋康萍, 等. 米氮平与帕罗西汀治疗抑郁症对照研究[J]. 临床精神医学杂志, 2006, 16(4): 235-236.
[10] 林卓毅, 余英仪, 陈永平. 米氮平与帕罗西汀治疗抑郁症对照研究[J]. 四川医学杂志, 2005, 26(11): 1229-1230.
[11] 刘文英, 廖春萍, 高欢. 米氮平与帕罗西汀治疗抑郁症对照研究[J]. 临床心身疾病杂志, 2007, 13(3): 200-202.
[12] 任宏泉, 过秋燕, 程茂巧, 等. 米氮平与帕罗西汀治疗抑郁症对照研究[J]. 临床精神医学杂志, 2004, 14(2): 88-89.
[13] 肖瑞林, 孔令军, 左小云. 米氮平与帕罗西汀治疗抑郁症对照研究[J]. 江西医药, 2006, 41(10): 788-789.
[14] 许俊杰 , 任静萱, 张炜. 米氮平与帕罗西汀治疗抑郁症对照研究[J]. 中国实用医药, 2011, 6(36): 161-162.
[15] 陈涛, 陈昌利, 江永, 等. 米氮平与帕罗西汀治疗抑郁症疗效对照[J]. 中国现代医生, 2009, 47(34): 38-39, 44.
[16] DeBoer T, Nefkens F, VanHelvoirt A. The alpha 2-adren- oceptor antagonist Org 3770 enhances serotonin transmis- sion in vivo[J]. Eur J Pharmacol, 1994, 253(1-2): 5-6.

[1]	. [J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2022, 52(9): 0-.